Skip to main content

Table 4 Comparison of Baseline Characteristics of Subgroup of Patients with Major Depressive Disorder (MDD) and Chronic Kidney Disease (CKD) with Controls without MDD

From: Association of platelet function with depression and its treatment with sertraline in patients with chronic kidney disease: analysis of a randomized trial

Variable

MDD+/CKD+ (n = 49)

MDD−/CKD+ (n = 28)

MDD−/CKD- (n = 15)

P-value

Age, years, mean ± SD

53 ± 12

52 ± 10

49 ± 11

0.55

BMI, kg/m2, mean ± SD

32.3 ± 9.9

32.0 ± 5.5

29.8 ± 4.9

0.56

Female, n (%)

20 (41)

16 (57)

8 (50)

0.38

African American, n (%)

27 (55)

15 (54)

4 (25)

0.14

Diabetes mellitus, n (%)

27 (55)

13 (46)

7 (44)

0.64

Proton pump inhibitor use, n (%)

10 (20)

1 (4)

1 (6)

0.07

Beta blocker use, n (%)

31 (63)

21 (75)

0 (0)

< 0.01

Statin use, n (%)

26 (53)

19 (68)

5 (31)

0.06

ACEI/ARB use, n (%)

24 (49)

12 (43)

5 (31)

0.46

eGFR, mL/min/1.73 m2, mean ± SD

22 ± 13a

17 ± 7a

101 ± 15b

< 0.01

Urine albumin-to-creatinine ratio, mg/g, median (IQR)

432 (27–4962)a

1282 (2–6469)b

5 (0–87)c

< 0.01

Hemoglobin, g/dL, mean ± SD

11.2 ± 2.1a

11.2 ± 1.7a

14.4 ± 1.7b

< 0.01

White blood cell count, K per μL, mean ± SD

7 ± 3

8 ± 2

6 ± 2

0.25

Platelet count, K per μL, mean ± SD

230 ± 80

232 ± 55

217 ± 55

0.77

Serum total cholesterol, mg/dL, mean ± SD

179 ± 54

170 ± 42

180 ± 33

0.72

Serum triglycerides, mg/dL, median (IQR)

131 (47–340)

124 (35–275)

112 (43–443)

0.85

Serum LDL, mg/dL, mean ± SD

92 ± 42

94 ± 38

102 ± 29

0.71

Serum total bilirubin, mg/dL, mean ± SD

0.5 ± 0.7

0.4 ± 0.2

0.7 ± 0.6

0.20

Hemoglobin A1c, %

6.4 ± 1.8

6.5 ± 1.5

6.2 ± 0.8

0.80

Serum albumin, g/dL, mean ± SD

3.7 ± 0.6

4.0 ± 0.5

4.2 ± 0.4

< 0.01

Serum uric acid, mg/dL, mean ± SD

7.7 ± 2.0

8.9 ± 2.0

5.1 ± 1.8

< 0.01

Serum calcium, mg/dL, mean ± SD

8.9 ± 0.9

9.1 ± 0.8

9.3 ± 0.3

0.11

Serum phosphorus, mg/dL, mean ± SD

4.6 ± 1.0a

4.6 ± 1.1a

3.3 ± 0.3b

< 0.01

Serum parathyroid hormone, pg/mL, median (IQR)

184 (11–708)a

170 (77–255)a

42 (27–82)b

< 0.01

Serum 25-hydroxyvitamin D, ng/mL, mean ± SD

27 ± 17

28 ± 14

29 ± 15

< 0.01

QIDS-SR16 score, median (IQR)

12 (5–19)a

4 (0–8)b

3 (0–9)b

< 0.01

  1. Abbreviations: ACEI/ARB Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, BMI Body mass index, eGFR Estimated glomerular filtration rate, IQR Interquartile range, LDL Low density lipoprotein, SD Standard deviation, QIDS-SR16 16-item Quick Inventory for Depression Symptomatology Self-Report
  2. For Gaussian continuous variables, means ±SD and P-values for the one way ANOVA F-test are reported. For non-Gaussian continuous variables, medians (minimum and maximum) and P-values for one way non-parametric ANOVA for the ranked outcomes F-test are reported. For categorical variables, P-values for the Pearson Chi-square test are reported. Pairwise comparisons using two sample t-test or Fisher’s exact test are reported when the overall F-test is significant; pairs with statistical differences have been designated with different alphabetical superscripts
  3. MDD+/CKD+ represents subgroup of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST) Study cohort with major depressive disorder plus chronic kidney disease with entry eGFR of < 30 ml/min/1.73m2. MDD−/CKD+ represents controls with chronic kidney disease with entry eGFR of < 30 ml/min/1.73m2 without major depressive disorder from the Whole Blood Platelet Aggregation in Chronic Kidney Disease on Aspirin (WiCKDonASA) study. MDD−/CKD- represents controls without major depressive disorder or chronic kidney disease from the WiCKDonASA study
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us